+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Rufinamide"

Lennox Gastaut Syndrome Market Report 2026 - Product Thumbnail Image

Lennox Gastaut Syndrome Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Lennox-Gastaut Syndrome Drug Market Report 2026 - Product Thumbnail Image

Lennox-Gastaut Syndrome Drug Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
From
From
From
  • 9 Results (Page 1 of 1)
Loading Indicator

Rufinamide is a medication used to treat seizures associated with Lennox-Gastaut syndrome, a rare form of epilepsy. It is classified as an anticonvulsant and works by decreasing the number of abnormal electrical signals in the brain. Rufinamide is typically used in combination with other anticonvulsants to control seizures. It is available in tablet and oral suspension form. Rufinamide is a relatively new drug in the Central Nervous System (CNS) drugs market. It is used to treat a rare form of epilepsy, making it a niche drug. It is typically used in combination with other anticonvulsants, which can help to reduce the risk of side effects. Several companies are involved in the Rufinamide market, including Eisai, Inc., Sun Pharmaceutical Industries Ltd., and Mylan N.V. These companies manufacture and distribute the drug in various countries around the world. Show Less Read more